BMS sues Teva over Reyataz ANDA
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb has filed a patent infringement suit in the US District Court for the District of Delaware against Teva Pharmaceutical Industries alleging patent infringement related to its proposed generic version of the HIV protease inhibitor, Reyataz (atazanavir sulfate), thus triggering a 30-month stay of approval while the legal challenge is fought.